title: 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
abstract: We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
authors.affiliation: Department of Internal Medicine III, University Hospital Olomouc and Medical Faculty of Palacky University Olomouc, Olomouc, Czech Republic. abretina@email.cz
authors.forename: Jiri
authors.initials: J
authors.lastname: Minarik
authors.forename: Viera
authors.initials: V
authors.lastname: Sandecka
authors.forename: Vladimir
authors.initials: V
authors.lastname: Maisnar
authors.forename: Evzen
authors.initials: E
authors.lastname: Gregora
authors.forename: Ivan
authors.initials: I
authors.lastname: Spicka
authors.forename: David
authors.initials: D
authors.lastname: Starostka
authors.forename: Hana
authors.initials: H
authors.lastname: Plonkova
authors.forename: Jiri
authors.initials: J
authors.lastname: Jarkovsky
authors.forename: Lenka
authors.initials: L
authors.lastname: Walterova
authors.forename: Marek
authors.initials: M
authors.lastname: Wrobel
authors.forename: Dagmar
authors.initials: D
authors.lastname: Adamova
authors.forename: Tomas
authors.initials: T
authors.lastname: Pika
authors.forename: Hana
authors.initials: H
authors.lastname: Melicharova
authors.forename: Ludek
authors.initials: L
authors.lastname: Pour
authors.forename: Jakub
authors.initials: J
authors.lastname: Radocha
authors.forename: Petr
authors.initials: P
authors.lastname: Pavlicek
authors.forename: Jan
authors.initials: J
authors.lastname: Straub
authors.forename: Jaromir
authors.initials: J
authors.lastname: Gumulec
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Bacovsky
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Adam
authors.forename: Vlastimil
authors.initials: V
authors.lastname: Scudla
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage; D013997:Time Factors; D055815:Young Adult
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone
keywords: Adverse events; Combined regimens; Multiple myeloma; Prognostic factors; Response rate; Thalidomide